Giuliano Berellini

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds

Franco Lombardo, Giuliano Berellini, R. Scott Obach · Drug Metabolism and Disposition · 2018 · 166 citations · Full text

Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation

Cheryl Carson, Pichai Raman, Jennifer Tullai et al. · PLoS ONE · 2015 · 108 citations · Full text

Trpc4/c5 Cation Channels, Trpc4 Channel, Cancer Biology +16

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

Franco Lombardo, Nigel J. Waters, Upendra A. Argikar et al. · The Journal of Clinical Pharmacology · 2012 · 96 citations

Physiologically-based Pharmacokinetic Modeling, Pharmacodynamic Modeling, Human Pharmacokinetic Prediction +17